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Objectives The aim of this study was to evaluate echocardiographic remodeling in permanent atrial fibrillation (AF) patients
treated with either lenient or strict rate control.
Background It is unknown whether in permanent AF, lenient rate control is associated with more adverse cardiac remodeling
than strict rate control.
Methods Echocardiography was conducted at baseline and at follow-up in 517 patients included in the RACE II (RAte Con-
trol Efficacy in permanent atrial fibrillation II) trial. Echocardiographic parameters were compared between pa-
tients randomized to lenient rate control (n  261) or strict rate control (n  256).
Results Baseline echocardiographic parameters were comparable between patients randomized to lenient and strict rate con-
trol. Between baseline and follow-up, significant adverse atrial or ventricular remodeling was not observed in either
group. There were also no significant differences in atrial and ventricular remodeling between patients who continu-
ously had heart rates between 80 and 110 beats/min and patients who continuously had heart rates 80 beats/min
during follow-up. Lenient rate control was not independently associated with changes in echocardiographic parame-
ters: mean adjusted effect on left atrial size was 1.6 mm (p  0.09) and 1.1 mm on left ventricular end-diastolic di-
ameter (p  0.23). Instead, female sex was independently associated with adverse remodeling: mean adjusted effect
on left atrial size was 2.4 mm (p  0.02) and 6.5 mm on left ventricular end-diastolic diameter (p  0.0001).
Conclusions Female sex, not lenient rate control, seemed to be associated with significant adverse cardiac remodeling in
patients with permanent AF such as those enrolled in the RACE II study. (RAte Control Efficacy in Permanent
Atrial Fibrillation [RACE II]; NCT00392613) (J Am Coll Cardiol 2011;58:942–9) © 2011 by the American Col-
lege of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.030Atrial fibrillation (AF) is the most common arrhythmia, its
incidence and prevalence increasing with age and life
expectancy (1). Nowadays, rate control therapy should be
the initial approach in elderly patients with mild symptoms
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August 23, 2011:942–9 Remodeling in Lenient Versus Strict Rate Controlthat lenient rate control is not inferior to strict rate control
in preventing cardiovascular events in patients with perma-
nent AF (6). However, long-standing AF may result in
adverse cardiac remodeling including atrial enlargement and
ventricular dysfunction (7,8), which could lead to stroke,
heart failure, and other cardiovascular events (9,10). It is
unknown whether lenient rate control is associated with
more adverse cardiac remodeling than strict rate control.
The aim of this predefined subanalysis of the RACE II
study was therefore to evaluate echocardiographic remodel-
ing in patients with permanent AF treated with lenient or
strict rate control.
Methods
The RACE II study. Patient characteristics and results of
the RACE II study were published previously (2,11). The
RACE II study was a randomized, multicenter study
comparing long-term effects of lenient and strict rate control
on morbidity and mortality in 614 patients with permanent
AF. Patients randomized to lenient rate control (which
allowed for a higher heart rate target than strict control) had
a resting heart rate target 110 beats/min. Patients ran-
omized to strict rate control had a resting heart rate target
80 beats/min and a heart rate target during moderate
xercise 110 beats/min. Patients were administered 1 or
ore negative dromotropic drugs (i.e., beta-blockers, non-
ihydropyridine calcium-channel blockers, digoxin) until
he heart rate target or targets were achieved. Follow-up
utpatient visits occurred every 2 weeks until the heart rate
arget or targets were achieved (dose-adjustment phase) and
n all patients after 1, 2, and 3 years. Follow-up was
erminated after a maximum period of 3 years or on June 30,
009, whichever came first. The study was approved by the
nstitutional review boards of all participating centers.
he present predefined study included only patients in
hom echocardiography was conducted at baseline and at
he end of the study; patients who died before the end of
he study (n  35) and patients with missing baseline
nd/or end of study echocardiograms (n  62) were
herefore excluded. There were neither statistical differ-
nces in baseline echocardiographic parameters between
he included and excluded patients nor specifically be-
ween the included patients and those who died before
he end of the study.
chocardiography. Primary endpoints in this study con-
isted of measures of structural atrial and ventricular
chocardiographic remodeling (i.e., changes in left atrial
ize, left atrial volume, and left ventricular end-diastolic
iameter). Left ventricular ejection fraction was not
ncluded as measure of remodeling because it cannot be
easured accurately during AF, especially when heart
ates are high. Two-dimensional transthoracic echocar-
iography was performed at the local hospitals at study
ntry and at the end of follow-up, after a median of
.0 years (interquartile range, 2.8 to 3.1 years). For left ctrial size, the anteroposterior
imension was measured from
he parasternal long-axis view
aken at end-systole. Left atrial
olume was calculated with the
llipsoid model using left atrial
iameters in the parasternal
ong axis, left atrial long axis, and left atrial short axis in
he apical 4-chamber view (12) and was available for 317
atients. Left ventricular end-diastolic diameter was
easured in the parasternal long-axis view. Echocardi-
graphy was performed in accordance with standard
ecommendations (12).
tatistical analysis. Baseline descriptive statistics are pre-
ented as mean  SD or median (interquartile range) for
ontinuous variables and numbers with percentages for
ategorical variables, as required. We evaluated differences
etween patients treated with lenient versus strict rate
ontrol using the chi-square test and Fisher exact test for
ategorical data, and the Student t test and Mann-Whitney
test for continuous data, depending on whether data were
ormally distributed. To compare echocardiographic pa-
ameters within patient groups, paired Student t test was
sed for the normally distributed data. Changes in echocar-
iographic parameters were also compared based on a
er-protocol analysis (i.e., between patients who continu-
usly had resting heart rates between 80 and 110 beats/min
nd patients who continuously had resting heart rates 80
eats/min during follow-up, after the dose-adjustment
hase). Patients who converted to sinus rhythm were
xcluded from the per-protocol analysis. Linear regression
as conducted to determine clinical characteristics related
o an increase in echocardiographic parameters. Univariate
inear regression was performed for all patient characteristics
i.e., randomization strategy, age, sex, duration of any AF,
uration of permanent AF, hypertension, coronary artery
isease, valvular heart disease, chronic obstructive pulmo-
ary disease, diabetes, previous heart failure hospitalization,
ody mass index, systolic and diastolic blood pressure, heart
ate at the end of the dose-adjustment phase, QRS duration,
reatinine, all medications at the end of the dose-adjustment
hase, and change in heart rate between baseline and the
nd of follow-up). Stepwise multivariable linear regression
nalysis was conducted using all variables with p  0.2 in
nivariate analysis, randomization strategy, and duration of
ny AF. Additional bootstrap analyses were performed to
ssess sensitivity of the multivariable models. For bootstrap
nalysis, automated stepwise variable selection was con-
ucted on 100 bootstrap samples using all variables with
 0.2 in univariate analysis. The multivariable models
ncluded all variables with p  0.05. Analyses were per-
ormed with STATA version 11.0 for Windows (Stata-
orp, College Station, Texas). In all analyses, p  0.05 was
Abbreviations
and Acronyms
AF  atrial fibrillation
RAAS  renin-angiotensin-
aldosterone-systemonsidered statistically significant.
m.
944 Smit et al. JACC Vol. 58, No. 9, 2011
Remodeling in Lenient Versus Strict Rate Control August 23, 2011:942–9Results
Patient characteristics. A total of 517 patients were in-
cluded in the study: 261 patients (50.5%) had been random-
ized to lenient rate control and 256 patients (49.5%) to strict
rate control (Table 1). Clinical characteristics were compa-
rable between the 2 groups, except that patients randomized
to lenient rate control more often had a history of coronary
artery disease resulting in more frequent statin use. After the
Patient CharacteristicsTable 1 Patient Characteristics
Len
Age, yrs
Male
Duration of any AF, months
Median
Interquartile range
Duration of permanent AF, months
Median
Interquartile range
Hypertension
Coronary artery disease
Valvular heart disease
Chronic obstructive pulmonary disease
Diabetes mellitus
Lone AF*
Previous hospitalization for heart failure
CHADS2 score
Symptoms
Palpitations
Dyspnea
Fatigue
New York Heart Association functional class
I
II
III
Body mass index, kg/m2
Blood pressure, mm Hg
Systolic
Diastolic
Heart rate, beats/min
Heart rate at inclusion
Heart rate at end of dose-adjustment phase
Rate control target achieved
QRS duration, ms
Creatinine, mol/l
Medication at end of dose-adjustment phase
Beta-blocker
Verapamil/diltiazem
Digoxin
RAAS inhibitor
Diuretic
Statin
Vitamin K antagonist
Aspirin
Values are mean  SD or n (%) unless otherwise indicated. *Lone AF
precipitating causes of AF.
AF  atrial fibrillation; RAAS  renin-angiotensin-aldosterone systedose-adjustment phase, patients randomized to lenient ratecontrol less often used beta-blockers, nondihydropyridine
calcium-channel blockers, and digoxin (Table 1). During
the course of the study, heart rates were significantly higher
in patients randomized to lenient rate control. The mean
resting heart rate at the end of the dose-adjustment phase
was 93 10 beats/min in the lenient rate control group and
76  12 beats/min in the strict rate control group (p 
0.001). After 1 and 2 years and at the end of follow-up, the
ate Control
261)
Strict Rate Control
(n  256) p Value
 8 68 9 0.45
(66.7) 166 (64.8) 0.66
0.27
5 20
–55 5–63
0.63
3 2
–6 1–5
(65.9) 153 (59.8) 0.15
(21.8) 37 (14.5) 0.03
(20.3) 55 (21.5) 0.74
(12.5) 37 (12.3) 0.29
(12.3) 26 (10.2) 0.45
(1.9) 5 (2.0) 0.55
(8.4) 27 (10.6) 0.41
 1.0 1.4 1.2 0.81
(57.1) 150 (58.6) 0.12
(21.5) 68 (26.6) 0.17
(34.9) 92 (35.9) 0.80
(28.4) 86 (33.6) 0.20
0.74
(65.1) 164 (64.1)
(29.5) 79 (30.9)
(5.4) 13 (5.1)
 4.7 28.6 4.5 0.95
 19 135 16 0.08
 12 82 11 0.005
 13 95 12 0.28
 10 76 12 0.001
(97.3) 168 (65.6) 0.001
 18 94 18 0.61
 23 95 23 0.60
(67.8) 201 (78.5) 0.006
(16.1) 97 (37.9) 0.001
(36.0) 152 (59.4) 0.001
(54.4) 128 (50.0) 0.32
(41.8) 105 (41.0) 0.86
(32.6) 61 (23.8) 0.03
(99.2) 253 (98.8) 0.64
(1.2) 3 (1.2) 0.98
ned as AF in the absence of cardiovascular disease and extracardiacient R
(n 
68
174
1
6
1
172
57
53
32
32
5
22
1.4
149
56
91
74
170
77
14
28.6
138
85
97
93
254
95
96
177
42
94
142
109
85
259
3
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August 23, 2011:942–9 Remodeling in Lenient Versus Strict Rate Controland 84 14 beats/min, respectively, in the lenient rate control
roup compared with 75 13 beats/min, 75 12 beats/min,
nd 75  14 beats/min, respectively, in the strict rate control
roup (p  0.001 for all comparisons between the 2 groups).
aseline diastolic blood pressure was significantly higher in
enient rate control patients and remained higher during the
ourse of the study; at the end of the study, diastolic blood
ressure was 82  11 mm Hg in lenient rate control patients
nd 80 11 mmHg in strict rate control patients (p 0.009).
ystolic blood pressures were generally similar between the 2
roups. Body mass index remained stable throughout the
tudy: mean body mass index at the end of the study was 28.4
4.5 kg/m2 in lenient rate control patients and 28.6  5.0
g/m2 in strict rate control patients. Thirty-eight patients
7.4%) converted to sinus rhythm during follow-up: 20 lenient
ate control patients (7.7%) and 18 strict rate control patients
6.8%) (p  0.08).
hanges in echocardiographic parameters. Baseline
chocardiographic parameters were comparable between
atients randomized to lenient and strict rate control; left
tria were slightly dilated, whereas left ventricular end-
iastolic diameters were within normal ranges (Table 2). At the
nd of follow-up, significant progression of adverse atrial or
entricular remodeling was not observed in either group.
urthermore, there were no significant differences in
hanges in echocardiographic parameters between patients
andomized to lenient and strict rate control, although there
as a tendency for lenient rate control to be associated with
relative left atrial size increase (mean difference in change
n atrial size, 1.6 mm; p  0.09). There were also no
ifferences in echocardiographic remodeling according to
er-protocol analysis (i.e., when comparing patients who
ontinuously had resting heart rates between 80 and 110
Echocardiographic Parameters According to Randomization StrategTable 2 Echocardiographic Parameters According to Randomiz
Echocardiographic
Parameter
Lenient Rate Control
Baseline
End of
Study  (95% CI)
LA size, mm 46.4 6.6 47.1 6.6 0.8 (0.5 to 2.0)
LA volume, ml (n 317) 71.7 26.6 76.7 24.9 5.0 (0.7 to 10.6
LV end-diastolic diameter, mm 51.1 7.4 50.8 6.9 0.3 (1.6 to 1.0)
Values are mean  SD unless otherwise indicated.
CI  confidence interval; LA  left atrial; LV  left ventricular;   change between baseline a
Echocardiographic Parameters According to Resting Heart Rate DuAfter the Dose-Adjustment PhaseTable 3 Echo ardiographic Parameters According to Resting HAfter the Dose-Adjustment Phase
Echocardiographic
Parameter
Heart Rate 80–110 Beats/Min
(n  329)
Baseline End of Study  (95% CI) Bas
LA size, mm 46.2 6.8 46.8 6.7 0.6 (0.5 to 1.7) 45.8
LA volume, ml 72.4 26.1 76.2 24.5 3.7 (1.3 to 8.8) 69.3
LV end-diastolic
diameter, mm
51.2 7.5 50.5 7.0 0.7 (1.9 to 0.5) 51.6Values are mean  SD unless otherwise indicated.
Abbreviations as in Table 1.eats/min with patients who continuously had resting
eart rates 80 beats/min after the dose-adjustment
hase) (Table 3). In the remaining small number of
atients with heart rates 110 beats/min during at least
follow-up visit, significant adverse remodeling was also
ot observed (Table 4).
linical factors associated with changes in atrial size.
enient rate control was not independently associated
ith changes in left atrial size (Table 5), although the p
alue neared significance, implying that there was a slight
endency for an association between lenient rate control
nd atrial size increase (mean adjusted effect, 1.6 mm;
 0.09). Female sex was independently associated with
n increase in left atrial size (mean adjusted effect, 2.4
m), whereas valvular heart disease, body mass index,
nd renin-angiotensin-aldosterone-system (RAAS) in-
ibitor use were associated with left atrial size decrease.
ootstrap analysis demonstrated similar results (data not
hown). Conversion to sinus rhythm was not associated
ith changes in atrial size, but the number of patients
onverting to sinus rhythm was very small.
linical factors associated with changes in ventricular
nd-diastolic diameter. Lenient rate control did not inde-
endently influence changes in left ventricular end-
iastolic diameter (Table 5). Again, female sex was
ssociated with adverse left ventricular remodeling (mean
djusted effect, 5.9 mm). Valvular heart disease, previous
ospitalization for heart failure, body mass index, and
AAS inhibitor use were independently associated with a
ecrease in left ventricular end-diastolic diameter (Table 5).
ootstrap analysis demonstrated similar results (data not
hown). Conversion to sinus rhythm was not associated with
Strategy
Strict Rate Control
Lenient vs. Strict
Rate Control
Baseline
End of
Study  (95% CI)
Difference in
 (95% CI) p Value
6.1 7.2 45.3 6.8 0.8 (2.1 to 0.5) 1.6 (0.3 to 3.4) 0.09
2.6 27.5 74.3 25.5 1.7 (4.4 to 7.7) 3.2 (5.0 to 11.5) 0.88
1.5 7.4 50.1 6.7 1.4 (2.7 to0.1) 1.1 (0.8 to 3.0) 0.24
of study.
All Follow-up VisitsRate During All Follow-up Visits
Heart Rate <80 Beats/Min
(n  120)
80–110 Beats/Min vs.
<80 Beats/Min
End of Study  (95% CI) Difference in  (95% CI) p Value
44.9 7.3 0.9 (3.0 to 1.1) 1.5 (0.8 to 3.8) 0.19
3 74.6 27.6 5.2 (4.2 to 14.6) 1.5 (11.5 to 8.6) 0.77
49.9 6.8 1.7 (3.7 to 0.2) 1.1 (1.3 to 3.4) 0.37yation
4
) 7
5ringeart
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 7.7
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Remodeling in Lenient Versus Strict Rate Control August 23, 2011:942–9changes in ventricular end-diastolic diameter taking into ac-
count the small number of patients converting to sinus rhythm.
Left atrial volume. In 317 patients, left atrial volume was
available at baseline and follow-up. Baseline characteris-
tics were comparable to those of the 517 patients of the
present study (data not shown). There were no significant
differences in left atrial volumes between patients ran-
Echocardiographic Parameters in Patients WithDuring at Least 1 Follow-up Vis tTable 4 Echo ardiogra hic Par m ters in PDuring at Least 1 Follow-up Visit
Echocardiographic Parameter Baseline
LA size, mm 48.1 7.6
LA volume, ml 82.0 28.8
LV end-diastolic diameter, mm 50.4 6.5
Values are mean  SD unless otherwise indicated.
Clinical Factors Associated With Changes in EcTable 5 Clinical Factors Associated With Ch
B (95%
Change in LA size, mm
Lenient rate control 1.6 (0.3
Female 1.8 (0.1
Duration of any AF 0 (0 to 0
Duration of permanent AF 0.1 (0.3
Valvular heart disease 2.2 (4.4
Previous heart failure hospitalization 2.1 (5.2
Body mass index, kg/m2 0.4 (0.6
Systolic blood pressure 0 (0.1
Diastolic blood pressure 0.1 (0.2
RAAS inhibitor 2.8 (4.7
Statin 1.9 (3.9
Change in heart rate 0 (0 to 0
Change in LA volume, % (n  317)
Lenient rate control 3.3 (5.0
Female 13.1 (4.4 to
Duration of any AF 0 (0.1
Body mass index, kg/m2 1.9 (2.8
Creatinine, 10 mol/l 1.7 (3.7
RAAS inhibitor 9.6 (17.8
Change in heart rate 0 (0.1
Change in LV end-diastolic diameter, mm
Lenient rate control 1.1 (0.8
Age 0.1 (0 to 0
Female 5.8 (3.9 to
Duration of any AF 0 (0.1
Valvular heart disease 1.9 (4.2
Previous heart failure hospitalization 4.7 (7.8
Body mass index, kg/m2 0.3 (0.5
QRS duration, 5 ms 0.4 (0.7
Creatinine, 10 mol/l 0.3 (0.8
Verapamil/diltiazem 1.6 (0.5
Digoxin 1.6 (3.4
RAAS inhibitor 3.3 (5.2
Change in heart rate 0 (0 to 0Abbreviations as in Tables 1 and 2.domized to lenient and strict rate control (Table 2).
During follow-up, left atrial volume had increased by 5.0
ml in the lenient rate control group and 1.7 ml in the
strict rate control group (p  NS). There were no
ignificant differences in changes in left atrial volume
etween both groups. Similar results were observed with
er-protocol analysis (Table 3). Lenient rate control was
t Rate >110 Beats/Mins With Heart Rate >110 Beats/Min
eart Rate >110 Beats/Min (n  32)
End of Study  (95% CI)
45.2 5.0 2.9 (6.8 to 0.9)
76.5 22.4 5.5 (24.2 to 13.1)
50.7 5.0 0.3 (2.7 to 3.3)
rdiographic Parameterss in Echocardiographic Parameters
sted Multivariable Analysis
p Value B (95% CI) p Value
0.09 1.6 (0.2 to 3.4) 0.09
0.06 2.4 (0.5 to 4.3) 0.02
0.98
0.13
0.06 3.2 (5.5 to1.0) 0.005
0.18
2) 0.0001 0.4 (0.6 to0.2) 0.0001
0.11
0.08
0) 0.002 2.1 (3.8 to0.2) 0.03
0.06
0.09
) 0.43 2.8 (5.4 to 10.9) 0.50
0.003 11.9 (3.2 to 20.6) 0.008
0.86
0) 0.0001 1.9 (2.8 to0.9) 0.0001
0.08
.5) 0.02
0.70
0.24 1.0 (0.8 to 2.8) 0.27
0.03
0.0001 6.5 (4.6 to 8.4) 0.0001
0.82
0.10 3.8 (6.0 to1.5) 0.001
6) 0.003 3.9 (6.9 to0.8) 0.01
1) 0.007 0.3 (0.5 to0.1) 0.004
2) 0.001
0.10
0.13
0.10
5) 0.0001 2.8 (4.6 to0.9) 0.003
0.80Hearatien
Hhocaange
Unadju
CI)
to 3.4)
to 3.8)
)
to 0)
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August 23, 2011:942–9 Remodeling in Lenient Versus Strict Rate Controlnot independently associated with left atrial volume
increase (Table 5). Instead, female sex was independently
associated with an increase in left atrial volume, whereas
body mass index was associated with left atrial volume
decrease. Bootstrap analysis demonstrated similar results
(data not shown).
Discussion
The present analysis of the RACE II study suggests that
stringency of rate control is not associated with significant
adverse cardiac remodeling in patients with permanent AF.
Instead, female sex seems to be related to adverse cardiac
remodeling, whereas treatment with RAAS inhibition and
increased baseline body mass index are associated with
reverse atrial and ventricular remodeling.
Influence of rate control strategy on atrial and ventricular
remodeling. Overall, we did not observe significant adverse
atrial or ventricular remodeling during 3-year follow-up in
these patients with permanent AF. More important, lenient
rate control did not cause significant adverse atrial and
ventricular remodeling compared with strict rate control.
There was a nonsignificant tendency that lenient rate
control was associated with a slight left atrial size increase.
This tendency was not observed regarding left atrial volume,
generally considered a more accurate measure of left atrial
size because of asymmetrical remodeling of the left atrial
chamber (12). The most essential finding was that lenient
rate control did not lead to adverse ventricular remodeling in
these permanent AF patients. Per-protocol analysis sup-
ported the finding that lenient rate control does not seem to
be associated with adverse remodeling because there were
no significant differences in atrial and ventricular remodel-
ing between patients with continuous resting heart rates
between 80 and 110 beats/min and patients with continuous
resting heart rates 80 beats/min after the dose-adjustment
phase. Heart rate 110 beats/min during at least 1
ollow-up visit was also not associated with significant
dverse remodeling, although this observation should be
nterpreted with caution due to the small patient number.
During follow-up, heart rates differed significantly be-
ween patients randomized to strict and lenient rate control.
ndeed, a trial evaluating high and low heart rates in AF
ould ideally bring all patients to the relevant rate targets.
owever, in the RACE II study and in this subanalysis, the
ctual average difference in heart rates between the 2 groups
uring total follow-up was approximately 10 beats/min (6).
ost patients were already using rate-controlling drugs at
nclusion, which implied that many lenient rate control
atients started off with heart rates 110 beats/min. In the
strict rate control group, the target was only achieved in 67%
of the patients, whereas in the lenient group, it was virtually
always achieved without much change in therapy. We
cannot exclude differences between strategies if we would
have had more effective means of strict rate control and if we
had kept heart rates just less than 110 in the lenient group. hPreviously we demonstrated that heart rates 100 beats/
min are associated with poor clinical outcome in AF
patients (13). Also in our main paper, we showed that event
rates were similar except for those with heart rates 100
beats/min in the strict group only. This group, however,
consisted of only a few patients (6). It may, therefore, still
seem to be uncertain whether heart rates between 100 and
110 beats/min are associated with worse outcome. The
current analysis at least demonstrates that with regard to
adverse atrial and ventricular remodeling, there are no
differences between a rate control strategy aiming at heart
rates 80 beats/min and a rate control strategy aiming at
heart rates 110 beats/min.
Previous studies demonstrated atrial enlargement as a
consequence of AF in contrast to our study (8,14,15). On
the other hand, regarding the ventricles, other studies have
demonstrated unchanged left ventricular end-diastolic di-
ameters in the presence of adequate rate control (14,15).
The absence of significant adverse remodeling in the present
study may be caused by improved therapies of associated
diseases, such as a more frequent use of RAAS inhibitors.
Indeed, we found that RAAS inhibitors were independently
associated with a decrease in left atrial size and in left
ventricular end-diastolic diameter. RAAS inhibitors are
known to induce reverse ventricular remodeling in heart
failure (16,17). Regarding atrial remodeling, RAAS inhib-
itors have been associated with left atrial size decrease in
patients with diastolic dysfunction (18) and in hypertensive
patients (19). Lack of angiotensin-converting enzyme in-
hibitor use was independently associated with atrial size
increase in a post hoc analysis of the RACE study (14).
Reversal of the process of atrial enlargement has been seen
after restoration of sinus rhythm (20,21), although we did
not find an association between conversion to sinus rhythm
and changes in atrial diameters. To our knowledge, the
present study is the first to observe that RAAS inhibition is
associated with reverse echocardiographic remodeling in
permanent AF patients.
Role of female sex and body mass index regarding cardiac
remodeling. Not stringency of rate control, but female sex
seemed to be associated with adverse cardiac remodeling.
There is increasing evidence that there are sex differences
regarding presentation, management, and outcome of car-
diovascular disease, being disadvantageous for females.
Women with AF treated with a rhythm control strategy
tend to have an adverse outcome compared with men (22).
urthermore, women carry an increased stroke risk (23).
lthough women are generally 5 years older than men when
hey first present with AF (24), differences in outcome of
ardiovascular disease may be caused by differences in
nherent biological factors, especially in post-menopausal
omen in whom potential protective effects of estrogens are
bsent. For example, gene expression profiles of patients
ith new-onset heart failure differ between males and
emales (25). In addition, male and female human hearts
ave significant differences in the composition of ion-
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rhythmias associated with repolarization abnormalities (26).
Possible differences in biological factors may explain why
females are more prone to adverse cardiac remodeling than
men.
In the present study, reverse atrial and ventricular remod-
eling was associated with increased baseline body mass
index, which at first glance seems to be an odd observation.
Increased body mass index has been associated with slightly
larger left ventricular end-diastolic diameters (27). Another
study observed in a general population that obesity resulted
in left atrial volume increase after 10 years’ follow-up (28).
In the present study, body mass index remained stable
during the course of follow-up, implying that reverse re-
modeling could not have been caused by a reduction in body
mass index. A possible explanation for the decrease in atrial
and ventricular diameters could be that, instead of eccentric
remodeling, concentric remodeling took place in patients
with an increased body mass index (29).
Study limitations. Both baseline and end-of-study echo-
cardiograms were necessary for the present analysis. This
means that patients who died before the end of the study
and patients with missing baseline and/or end of study
echocardiograms were excluded. The extent of adverse
cardiac remodeling in those patients is therefore unknown.
However, we believe that this does not create a bias because
in the main study, mortality was comparable in both lenient
rate control and strict rate control, and baseline character-
istics including baseline echocardiographic parameters in
the present analysis were comparable with those of the main
study.
Conclusion
In patients with permanent AF such as those enrolled in the
RACE II study, female sex, not lenient rate control, seemed
to be associated with significant adverse cardiac remodeling.
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